⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 4, 1988JNCI Journal of the National Cancer Institute

Interferons in Malignancy: Biological Products or Biological Response Modifiers?

View at Publisher

Ask AI

Bookmark

Share

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Abstract

Susan E. Krown; Interferons in Malignancy: Biological Products or Biological Response Modifiers?, JNCI: Journal of the National Cancer Institute, Volume 80, Iss

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Susan E. Krown (1988) studied this question.

synapsesocial.com/papers/6ac49ae6045e34bebf2eb203 https://doi.org/10.1093/jnci/80.5.306

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1The ethical dilemma of excluding patients from clinical trials based on language preferenceJNCI Journal of the National Cancer Institute · 2026
2Treatment-related neutropenia as predictor of response to adjuvant palbociclib in the PALLAS trial (ABCSG-42/AFT-05/BIG-14-13/PrE0109)JNCI Journal of the National Cancer Institute · 2026
3Modeling neoadjuvant treatment plus additional therapy effects on US population breast cancer mortalityJNCI Journal of the National Cancer Institute · 2026
4Electronic health record embedded frailty index and outcomes among older adults receiving cancer chemotherapyJNCI Journal of the National Cancer Institute · 2026
5Statewide surveillance of colorectal cancer screening using geospatial and Multi-Payer claims dataJNCI Journal of the National Cancer Institute · 2026
6Subgroup variations in benefit from telehealth palliative care for advanced lung cancerJNCI Journal of the National Cancer Institute · 2026
7Head and neck cancer in older adults: biological aging, treatment tolerance, and survivorshipJNCI Journal of the National Cancer Institute · 2026
8Employment after curative breast cancer treatment: the breast cancer and the workforce cohort studyJNCI Journal of the National Cancer Institute · 2026
9A clinical model incorporating early lymphocyte dynamics in HER2-positive breast cancerJNCI Journal of the National Cancer Institute · 2026
10Efficacy and toxicity of antibody-drug conjugates in older adults with breast cancer: A systematic review and meta-analysisJNCI Journal of the National Cancer Institute · 2026

More from JNCI Journal of the National Cancer Institute

More from Memorial Sloan Kettering Cancer Center